Literature DB >> 11937660

Epidemiological study of multiple sclerosis in Hong Kong Chinese: questionnaire survey.

K K Lau1, L K S Wong, L S W Li, Y W Chan, H L Li, V Wong.   

Abstract

OBJECTIVE: To study the epidemiology of multiple sclerosis in Hong Kong Chinese.
DESIGN: Cross-sectional questionnaire survey.
SETTING: Neurology and paediatric neurology departments in Hong Kong from January through June 1999. PARTICIPANTS: All confirmed multiple sclerosis patients. MAIN OUTCOME MEASURES: Demographic data, investigation results, Kurtzke's Expanded Disability Status Scale during the last follow-up visit, number of relapses between 1997 and 1998, and treatments used/currently in use.
RESULTS: Fifty-three Chinese multiple sclerosis patients were identified. The prevalence was thus estimated to be 0.77 per 100,000 population. This low prevalence was also noted in other multiple sclerosis studies from South-East Asia (range, 0.8-4 per 100,000 population). The female to male ratio among the Chinese multiple sclerosis sufferers was 9.6:1, a figure somewhat higher than that reported in the other studies from South-East Asia (range, 3.2-6.6:1). The Chinese multiple sclerosis patients in this study also had a high spinal cord involvement (66%) and a low presence of cerebrospinal fluid oligoclonal banding (40%). These findings were different from those in Caucasian multiple sclerosis patients.
CONCLUSION: Multiple sclerosis in Hong Kong Chinese has a low prevalence, a high female to male ratio, and a low cerebrospinal fluid oligoclonal banding presence.

Entities:  

Mesh:

Year:  2002        PMID: 11937660

Source DB:  PubMed          Journal:  Hong Kong Med J        ISSN: 1024-2708            Impact factor:   2.227


  12 in total

1.  Management of optic neuritis.

Authors:  Vimla Menon; Rohit Saxena; Ruby Misra; Swati Phuljhele
Journal:  Indian J Ophthalmol       Date:  2011 Mar-Apr       Impact factor: 1.848

2.  Sleep disorders in patients with multiple sclerosis in China.

Authors:  Shengli Ma; Xue Rui; Peiyi Qi; Gangqiong Liu; Jing Yang
Journal:  Sleep Breath       Date:  2016-10-11       Impact factor: 2.816

3.  Autologous peripheral blood stem cell transplantation for severe multiple sclerosis.

Authors:  Li Su; Juan Xu; Bing-Xin Ji; Sui-Gui Wan; Cong-Yan Lu; Hui-Qing Dong; Yue-Yi Yu; Dao-Pei Lu
Journal:  Int J Hematol       Date:  2006-10       Impact factor: 2.490

4.  Early relapse in multiple sclerosis-associated optic neuritis following the use of interferon beta-1a in Chinese patients.

Authors:  An-Guor Wang; Yen-Ching Lin; Shuu-Jiun Wang; Ching-Piao Tsai; May-Yung Yen
Journal:  Jpn J Ophthalmol       Date:  2006-12-18       Impact factor: 2.447

5.  CSF pleocytosis and expansion of spinal lesions in Japanese multiple sclerosis with special reference to the new diagnostic criteria.

Authors:  Toshiyuki Fukazawa; Seiji Kikuchi; Ryuji Miyagishi; Yusei Miyazaki; Hikoaki Fukaura; Ichiro Yabe; Takeshi Hamada; Kunio Tashiro; Hidenao Sasaki
Journal:  J Neurol       Date:  2005-03-06       Impact factor: 4.849

Review 6.  Review of the diagnosis and clinical features of multiple sclerosis in China.

Authors:  Xiao-Juan Cheng; Li-Zhen Xu
Journal:  Neurosci Bull       Date:  2009-02       Impact factor: 5.203

7.  Neuromyelitis optica: an antibody-mediated disorder of the central nervous system.

Authors:  Jiwon Oh; Michael Levy
Journal:  Neurol Res Int       Date:  2012-01-29

8.  Prevalence and Incidence of Multiple Sclerosis in Fars Province, Southern Iran.

Authors:  Sadegh Izadi; Ali Reza Nikseresht; Maryam Poursadeghfard; Afshin Borhanihaghighi; Seyyed Taghi Heydari
Journal:  Iran J Med Sci       Date:  2015-09

Review 9.  Epidemiology of neuromyelitis optica in the world: a systematic review and meta-analysis.

Authors:  Masoud Etemadifar; Zahra Nasr; Behrang Khalili; Maryam Taherioun; Reza Vosoughi
Journal:  Mult Scler Int       Date:  2015-04-20

10.  Multiple sclerosis: clinical features and MRI findings in Northern China.

Authors:  Tianran Li; Hui Xiao; Shengjun Li; Xiangke Du; Jun Zhou
Journal:  Eur J Med Res       Date:  2014-04-15       Impact factor: 2.175

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.